The in vivo interactions of cilofungin, an echinocandin antifungal agent, and amphotericin B, a polyene derivative, in a murine model of disseminated candidiasis have been investigated. While single therapy with either drug alone prolonged survival of infected mice, kidney colony counts were not appreciably reduced. In contrast, combination therapy, especially at higher doses of both drugs, resulted in significant prolongation of survival and suppression of growth of yeast cells in the kidneys. Combination therapy of experimental candidiasis with cilofungin and amphotericin B did not result in antagonism; rather, additive or synergistic effects were seen. Future preclinical work with other echinocandin and polyene derivatives should include studies evaluating the in vivo interactions of both classes of compounds.
Cilofungin is a derivative of echinocandin and displays potent antifungal activity in animal models of candidiasis, with restricted in vitro activity against Candida albicans and C. tropicalis (3, 6, 7) . While in vitro data have documented the occurrence of antagonism of antifungal effect when cilofungin is combined with amphotericin B (1), in vitro susceptibility tests are unreliable in predicting in vivo activities of antifungal drugs (2) . For this reason, animal models of mycoses have been used to evaluate the potential utility of new compounds for use as antifungal drugs (8) . Cilofungin has demonstrated activity in animal models of candidiasis (5, 9) . While the present paper was in review, a recent study evaluating the interactions of amphotericin B and cilofungin in a murine model of candidiasis was published (4) . We alone were dead by the fifth day. These mice all died early in the treatment course, suggesting either drug toxicity or trauma related to intraperitoneal injections as the cause. Similar increases in mortality with low doses of cilofungin were not seen in two other experiments, arguing against drug toxicity as a cause of the increased mortality. Treatment with amphotericin B alone at low (0.1-mg/kg/day) and high (1-mg/kg/day) doses resulted in improved survival compared with that of controls (38 and 25 versus 12%, respectively), but these results did not achieve statistical significance. Similarly, 50% of the mice receiving high doses of cilofungin survived (Fig. 1B) .
When cilofungin was combined with amphotericin B, low doses of both drugs were not superior to low doses of amphotericin B alone (Fig. 1A) . However, all of the mice treated with high-dose combination therapy survived ( Fig.  1B ; P < 0.003), thus demonstrating an additive or synergistic effect of the two drugs.
In a second experiment, mice received 3.8 x 106 yeast cells. Treatment was begun 24 h after inoculation and continued for 10 days. By day 11, 75% of the control mice were dead (Fig. 2A) . Low-dose cilofungin slightly increased survival. However, the best treatment results were seen with high-dose combination therapy ( Fig. 2B ; P = 0.01 compared with control, P = 0.058 compared with high-dose cilofungin alone, and P = 0.14 compared with high-dose amphotericin B alone), followed by low-dose combination therapy (P = 0.003 compared with control, P = 0.015 compared with low-dose cilofungin alone, and P = 0.073 compared with low-dose amphotericin B alone).
In the same experiment, the times required to reach the LD50 were 4 days in the control mice; 9 and 16.5 days in mice receiving low-and high-dose cilofungin, respectively; and 15 days in mice receiving low-dose amphotericin B. An LD50 was not achieved in either of the combination therapy groups or in the high-dose amphotericin B group. Thus, by this criterion, combination therapy resulted in improved survival compared with cilofungin alone and low-dose amphotericin B alone.
Results of kidney cultures obtained during the experiment whose results are presented in Fig. 2 confirm the increased activity of combination therapy compared with that of treatment with each drug individually ( Table 1) . On day 14, 3 days after therapy was discontinued, a decrease in yeasts recovered from kidneys was found only in the combination therapy groups (P c 0.041). An approximate one-log increase in CFU was seen in the other groups (P < 0.001). At the end of therapy, a large decrease in CFU recovered from the kidneys was found only in both groups that received combination therapy (P < 0.001). A decrease in numbers of colonies was also seen in both amphotericin B groups (P < 0.001). Cilofungin at either dose appeared to have a fungistatic effect, since the numbers of organisms recovered on the first day of therapy were similar to those recovered at the completion of therapy.
This study clearly demonstrates that in a murine model of disseminated candidiasis, therapy with the echinocandin analog cilofungin in combination with amphotericin B results in a better outcome than that obtained with either drug used alone. It is particularly noteworthy that there was no antagonism observed, in contrast to results obtained from in vitro studies (1) . The additive or synergistic activity was observed both in improvements in survival and in colony counts from kidneys, a major target organ in experimental candidiasis. These results support the conclusions of Hanson et al., who found that 2 of 12 mice had sterile kidneys when treated with cilofungin (6.25 or 62.5 mg/kg/day) plus amphotericin B (0.625 mg/kg/day), we did not find sterile kidneys in our study.
While clinical investigation of cilofungin has been discontinued, echinocandin derivatives are attractive agents since they have a mode of action different from that of the currently available major antifungal classes, polyenes and azoles. The finding that combination therapy with cilofungin and amphotericin B can be more effective than monotherapy suggests that future studies evaluate the interactions of the different classes of drugs in experimental models of fungal The expert technical assistance of Lizanne Nobel is also acknowledged.
